HEALTH TECHNOLOGY

Paradigm Oral Health Announces Acquisition by BlackRock Long Term Private Capital

Paradigm Oral Health | September 23, 2022 | Read time : 04:00 min

Paradigm Oral

Paradigm Oral Health a leading oral surgery and digital dentistry platform announced that BlackRock Long Term Private Capital has entered into a definitive agreement to acquire a majority interest in the company from shareholders including InTandem Capital Partners. LTPC will partner with Paradigm’s executive leadership team, led by founder and CEO Dr. David Rallis, to support the company’s continued expansion and strategic growth plans.

Founded in 2018, Paradigm has developed an industry-leading model designed to attract and retain best-in-class surgeons focused on delivering the highest quality of oral health care and dental implant surgery while fostering a medically-driven, patient-friendly culture of excellence. The company partners with leading oral surgery groups in markets across the United States, allowing them to maintain their unique brand identity while operating on the same platform. Paradigm’s proprietary practice management technology, Paragon, utilizes cutting-edge technology and data analytics to provide and store proprietary information and intelligence generated by the business, leading to enhanced performance as well as increased patient and provider satisfaction. Today, Paradigm and its team of over 100 surgeon partners provide patient care in 75 state-of-the-art facilities throughout the United States.

We are pleased to invest in Paradigm, which has established itself as an industry defining platform for the development and delivery of next-generation oral health solutions. Through its focus on providing superior clinical care, advanced technology, and continued training and education to its surgeon partners, the company is well positioned for long-term growth. We look forward to partnering with Dr. David Rallis and the entire Paradigm team.”

Colm Lanigan, Head of BlackRock LTPC, Americas

David Rallis, DDS, MD, and CEO of Paradigm Oral Health, commented, “Paradigm is advancing oral surgical outcomes and patient experience through a culture that places the needs of the patient first. At Paradigm, we validate our clinical performance through a proprietary data ecosystem and use data to reinforce our culture of excellence and accountability. Through innovation, and the rapid adoption of technology, we continue to set the standard for dental implant surgery. Aligning our company with world-class partners, first InTandem Capital and now BlackRock LTPC, has allowed Paradigm to emerge as a leader. We are humbled by the opportunity to partner with BlackRock LTPC, and excited to work with Colm Lanigan and his team as we continue to advance Paradigm as the global leader in oral surgery.”

Elliot Cooperstone, Managing Partner of InTandem Capital Partners, Paradigm’s financial sponsor since 2019, commented, “InTandem Capital invests in healthcare companies that are local leaders with the ambition and potential to become a national powerhouse. Dr. David Rallis and the leadership team at Paradigm embraced our playbook for accelerated growth with amazing skill and dedication. Our deep trust in each other has allowed our partnership to flourish. My colleagues and I wish David and the Paradigm team the very best as they build on their well-deserved position as the country’s leading oral health company.”

Paradigm is BlackRock LTPC’s sixth investment to date and its fourth investment in North America.

Houlihan Lokey acted as financial advisor and Goodwin Procter acted as legal advisor to Paradigm. Simpson Thacher acted as legal advisor to Blackrock LTPC.

About Paradigm Oral Health
Paradigm Oral Health is the preeminent provider of oral surgery. Paradigm’s uniqueness comes from their ability to hire the most elite oral surgeons in the country and train them on their proprietary platform of excellence. Paradigm Oral Health continues to revolutionize and reinvent implant surgery through their ongoing technology and digital work-flow advancements. With a passion for excellence, Paradigm embraces every opportunity to meet the needs of their patients and referring dentists. 

About BlackRock LTPC
BlackRock LTPC is an innovative private equity strategy focused on investing in high-quality businesses and value creation through active collaboration with management teams. The strategy's flexible duration and prudent approach to leverage preserve optionality for growth and help enable compounded capital appreciation. LTPC's team of 23 professionals are based in New York and London and invest across North America and Western Europe. LTPC is backed by BlackRock, Inc., which manages $320 billion in alternative investments and commitments on behalf of clients worldwide as of June 30, 2022. 

About InTandem Capital Partners
InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build excellent businesses of significant value working collaboratively with its management team partners. InTandem is comprised of former business executives and experienced investors, and is uniquely qualified to provide strategic, acquisition and operating expertise to help companies significantly increase their value over time. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities. 

Spotlight

As a TRICARE® beneficiary, it is easier than ever to stay on top of your pharmacy benefit and your prescription activity. By regularly reviewing your pharmacy Explanation of Benefits (EOB) statements, you’ll always be sure to have the latest history of your pharmacy benefit use.

Spotlight

As a TRICARE® beneficiary, it is easier than ever to stay on top of your pharmacy benefit and your prescription activity. By regularly reviewing your pharmacy Explanation of Benefits (EOB) statements, you’ll always be sure to have the latest history of your pharmacy benefit use.

Related News

HEALTH TECHNOLOGY

GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity

GE Healthcare | November 18, 2022

GE Healthcare’s Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients site in Lindesnes, Norway. The investmentwhich is creating around 100 new jobs – is part of GE Healthcare’s broader commitment to address significant future global demand for iodinated contrast media, used in Xray and Computed Tomography procedures around the world to enhance visualization of organs, blood vessels and tissues across disease pathways. Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second. This new investment, coupled with the recent opening of a new production line at GE Healthcare’s Cork, Ireland, fill and finish facility, aims to enable the production of 30 million more patient doses per year by 2025. “We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures. This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe.” President & CEO of GE Healthcare Pharmaceutical Diagnostics, Kevin O’Neill The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API. Recently, GE Healthcare announced a multi-year agreement with SQM, a Chile-based mining company, to secure increasing supply of iodine, the key ingredient in iodinated contrast media. GE Healthcare is the world’s leading supplier of contrast media, used to support patient imaging procedures in 130+ countries globally. All stages of its contrast media manufacturing, from development of Active Pharmaceutical Ingredient (API) to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices. With over 4000 employees globally and seven manufacturing sites, the Pharmaceutical Diagnostics business also develops and supplies radiopharmaceuticals used to support diagnosis, monitoring and treatment selection across Neurology, Cardiology and Oncology clinical pathways. About GE Healthcare GE Healthcare is the $17.7 billion healthcare business of GE. As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Read More

FUTURE OF HEALTHCARE

Alight Announces Network Agreement With Children’s Hospital Colorado

Alight Solutions and Children’s Hospital Colorado | September 09, 2022

Alight, Inc. a leading cloud-based human capital technology and services provider announced an institutional agreement with Children’s Hospital Colorado one of the nation’s premier pediatric healthcare systems, to join Alight’s Expert Physician Network. This collaboration further expands Alight’s ability to provide employees and their loved ones guidance from the nation’s leading specialists when facing a new or complex diagnosis. Through the agreement, families will now have access to the Children’s Colorado world-class network of physicians when seeking an expert opinion from Alight, providing the opportunity to drive more informed health decisions before, during and after treatment, as well as improved patient outcomes and lower costs for users. “We are delighted to join forces with Children’s Colorado’s network of physicians, further demonstrating Alight’s leadership in healthcare navigation. Our expanding work among the nation’s preeminent hospitals accentuates our commitment to delivering the people we serve with the best guidance and technology possible, especially in this instance when children are directly impacted.” Bipin Mistry, Chief Medical Officer at Alight The Expert Physician Network is made up of over 2,000 of the nation’s top physicians. Using Alight’s award-winning platform for virtual expert opinions, these specialists collaborate with Alight’s team to respond to participant questions, provide guidance on diagnoses and treatment options they have received from their provider, and work together with other leading specialists to deliver multidisciplinary opinions when needed. “By providing this service, we can provide more children the comprehensive, world-class expertise offered by Children’s Colorado, while keeping them close to home,” said Raphe Schwartz, Chief Strategy Officer at Children’s Hospital Colorado. “With this collaboration, we are thrilled to be able to support children and families nationwide by providing them with high-quality, family-centered guidance when they need an expert opinion.” About Alight Solutions Alight is a leading cloud-based human capital technology and services provider that powers confident health, wealth and wellbeing decisions for 36 million people and dependents. Our Alight Worklife® platform combines data and analytics with a simple, seamless user experience. Supported by our global delivery capabilities, Alight Worklife is transforming the employee experience for people around the world. With personalized, data-driven health, wealth, pay and wellbeing insights, Alight brings people the security of better outcomes and peace of mind throughout life’s big moments and most important decisions. About Children’s Hospital Colorado Children’s Hospital Colorado is one of the nation’s leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and recognized as a top 10 children’s hospital by U.S. News & World Report, Children’s Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children’s Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region.

Read More

HEALTHTECH SECURITY, FUTURE OF HEALTHCARE

Magellan Healthcare Teams with Kyo to Improve Autism Outcomes

Magellan Health | December 07, 2022

Magellan Healthcare, Inc., the behavioral health division of Magellan Health, Inc., announced the launch of a first-to-market, value-based collaboration with Kyo Autism Therapy, LLC, a California-based Applied Behavior Analysis provider, to drive meaningful and objectively measurable outcomes for children with autism spectrum disorder. Magellan and Kyo will develop, build and test a value-based model for treatment planning and delivery to continuously improve care for children with ASD and help the families who care for them. Findings will be used to establish evidence-based practices and drive outcomes-based programs across the ABA industry. Magellan manages ABA services through Magellan Autism Connections®, a first-to-market and one-of-a-kind solution that offers individualized care planning to optimize treatment and services. Enhanced care coordination ensures goals are met, with services that include intensive support to caregivers. Magellan Autism Connections® includes a fully vetted and credentialed provider network, of which Kyo is a member, the members of which share the company’s mission to deliver evidence-based ASD treatment that drives positive outcomes. When surveyed, 93% of Magellan Autism Connections® members’ caregivers say service providers work well with them and their child and caregivers have learned how to use ABA techniques to help their child. In addition, 80% of commercial Magellan Autism Connections® members make excellent progress at a cost 40% below the national average, and 75% of Medicaid members make excellent progress at a cost 62% below the national average. “At Magellan, we have deep clinical expertise in ABA that includes strong collaborations with well-respected providers such as Kyo. Together with Kyo’s individualized and customized approach to ABA therapy, we can jointly improve the quality of life for children with autism and their families.” Yagnesh Vadgama, BCBA, vice president, clinical care services for autism, Magellan Healthcare "ABA services have struggled to transition from a fee-for-service to a value-based model," said Colin Davitian, CEO of Kyo. "Our collaboration with Magellan will help change the paradigm and make ABA treatment more individualized and outcomes-driven.” About Magellan Health Magellan Health, Inc. a is a leader in managing the fastest growing, most complex areas of health, including special populations, and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. About Magellan Healthcare Magellan Healthcare, Inc., the healthcare business unit of Magellan Health, Inc., offers solutions for complex conditions in the areas of behavioral health and medical specialty treatment. Magellan Healthcare and its subsidiaries serve commercial health plans, employers, state and local governments, and the Federal government, including the Department of Defense. About Kyo Kyo Autism Therapy, LLC is a leader in behavior therapy for individuals with autism. With its staff of highly-educated, expertly trained professionals, Kyo works to advance the lives of individuals and families with autism and other special needs through compassionate, evidence-based treatment. Since being founded in 2005, Kyo has expanded from its San Francisco base to serve families across California and the U.S.

Read More